Cara Therapeutics Inc
Research Cara Therapeutics Inc (TVRD) on Bullrun: market cap USD 17.07M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTVRD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 17.07M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 15.44M
- Free cash flow-USD 21.67M
Valuation Snapshot
latest market cap is USD 17.07M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.57M | -USD 18.21M | -USD 23.50M | n/a | -3.26 | USD 20.73M | USD 201.00K | USD 20.95M |
| FY2024 | USD 7.14M | -USD 29.40M | -USD 19.35M | n/a | -11.42 | USD 31.61M | USD 30.56M | -USD 91.13M |
| FY2023 | USD 20.97M | -USD 11.85M | -USD 94.45M | n/a | -26.26 | USD 51.78M | USD 368.00K | -USD 62.06M |
| FY2022 | USD 41.87M | -USD 85.47M | -USD 78.77M | n/a | -19.12 | USD 63.74M | n/a | USD 158.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 17.07M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 40.34M | n/a | n/a | n/a |
| 2021 | 2021-12-30 | n/a | 25.4 | n/a | n/a |
About Cara Therapeutics Inc
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cara Therapeutics Inc's market cap?
Cara Therapeutics Inc's market capitalization is USD 17.07M.
What does Cara Therapeutics Inc do?
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.